Evidence map›Paper›PMID 38659630›Full record

SynthesisClinical practice and epidemiology in mental health : CP & EMH2023

The Effects of Tyrosine Kinase Inhibitors (TKIs) in Monotherapy and with Add-on Treatments on Health-related Quality of Life of People with Chronic Myeloid Leukemia: A Systematic Review of Randomized-Controlled Trials.

Antonio E Nardi, Federica Sancassiani, Vanessa Barrui, Goce Kalcev, Veronica Uras, Giulia Meloni, Luigi Marongiu, Giorgio Tamburini, Alberto Maleci, Laiana A Quagliato and 2 more

Open access · diamondAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical practice and epidemiology in mental health : CP & EMH, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Antonio E NardiInstitute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Federica SancassianiDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Vanessa BarruiDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Goce KalcevDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Veronica UrasDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Giulia MeloniDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Luigi MarongiuDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Giorgio TamburiniDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Alberto MaleciDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Laiana A QuagliatoInstitute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Giorgio La NasaDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Mauro Giovanni CartaDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
University of Cagliari · ITUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The era of establishing tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) changed the outcome and the course of this life-threatening malignancy. People suffering from CML have now a better prognosis and a longer life expectancy due to the development of TKIs, even if it requires long-term, often lifelong, treatments that are nonetheless associated with improved Health-related Quality of life (HRQoL). However, data on the effects of TKIs on HRQoL are not always systematic; sometimes the data have been obtained by studies different from RCTs, or without a clear definition of what HRQoL is. The main purpose of this systematic review is to summarize all randomized-controlled trials (RCTs) including HRQoL as main or secondary outcome in patients with CML treated with TKIs or with TKIs plus an add-on treatment. Methods: A systematic review has been conducted by searching the relevant papers in PubMed/Medline and Web of Science with the following keywords: "quality of life" OR "health-related quality of life" OR "QoL" OR "HRQoL" OR "H-QoL" AND "chronic myeloid leukemia". Interval was set from January 2000 to December 2020. Results: 40 papers were identified through the search. Out of them, 7 RCTs were included. All the studies used standardized measures to assess HRQoL, even not always specific for CML. 5 RCTs randomized subjects to 2 or 3 arms to evaluate the effects of TKIs of the first, second and third generation in monotherapy. 2 RCTs randomized subjects to TKI therapy plus an add-on treatment Conclusion: All the included RCTs pointed out significant findings regarding the positive effects of TKIs on HRQoL of people with CML, both when they were used in monotherapy or, notably, with an add-on treatment to enhance TKIs effects.

Indexed as

Chronic myeloid leukemiaHealth related quality of lifeHematologyPsycho-oncologyPsychosocial healthSystematic review

Identifiers

PMID38659630
PMCPMC11037549
OpenAlexW4312921229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.